HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Find → Understand → Decide

Dexamethasone

Discovery priority: LOW · POSSIBLE / INVESTIGATE

Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.

Why investigate?

Why stranded (event context): efficacy failure; inadequate public evidence; safety failure

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN

Biology implicated: UNCLEAR · Failure context: DRUG/BIOLOGY

MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.

Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN

Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.

Existing buyer gates

Human Signal: UNKNOWN

Cheap Truth: UNKNOWN

Clean Rights: UNKNOWN

Market Pull: UNKNOWN

No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.

Evidence timeline

2026-06-18 · trial:NCT00253318

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Toxicity and Lack of Efficacy

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: efficacy failure; safety failure · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "b09f3760692dffa9455a5d24de29c9532ea14ea5070d59bf9573597b987fb49a",
  "metadata": {
    "complete": false,
    "content_hash": "0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7",
    "failed": false,
    "last_checked": 1790026980.1182604,
    "last_success": 1790026980.1182604,
    "live_verified": true,
    "scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7",
  "raw_path": "research/obz7_sources/0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT00253318"
}

2026-09-03 · trial:NCT06232044

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Enrollment to Dose Level 1 cohort has been met

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "19b74033e89284177b29d5dc2509105709d1d1a726e3344d17be027ca6825bbe",
  "metadata": {
    "complete": false,
    "content_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
    "failed": false,
    "last_checked": 1790026985.182528,
    "last_success": 1790026985.182528,
    "live_verified": true,
    "scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
  "raw_path": "research/obz7_sources/2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT06232044"
}

Freshness is claim-specific

Fetching an old filing today does not establish current ownership or program status.

pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.118260+00:00

clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:05.182528+00:00

Registry observations (3)

NCT00253318 · TERMINATED · PHASE1 · Breast Cancer · Trial sponsor M.D. Anderson Cancer Center

Reported aliases: Decadron. Identity, treatment role and exposure require review.

NCT06232044 · SUSPENDED · PHASE1, PHASE2 · Recurrent Multiple Myeloma; Refractory Multiple Myeloma · Trial sponsor Alliance for Clinical Trials in Oncology

Reported aliases: None. Identity, treatment role and exposure require review.

NCT01936532 · COMPLETED · PHASE2 · Newly Diagnosed Multiple Myeloma · Trial sponsor Nantes University Hospital

Reported aliases: None. Identity, treatment role and exposure require review.

Back to discovery